GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scopus BioPharma Inc (OTCPK:SCPS) » Definitions » 5-Day RSI

Scopus BioPharma (Scopus BioPharma) 5-Day RSI : 15.46 (As of Jun. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Scopus BioPharma 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-06-06), Scopus BioPharma's 5-Day RSI is 15.46.

The industry rank for Scopus BioPharma's 5-Day RSI or its related term are showing as below:

SCPS's 5-Day RSI is ranked better than
92.66% of 1566 companies
in the Biotechnology industry
Industry Median: 47.825 vs SCPS: 15.46

Competitive Comparison of Scopus BioPharma's 5-Day RSI

For the Biotechnology subindustry, Scopus BioPharma's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scopus BioPharma's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scopus BioPharma's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Scopus BioPharma's 5-Day RSI falls into.



Scopus BioPharma  (OTCPK:SCPS) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scopus BioPharma  (OTCPK:SCPS) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Scopus BioPharma 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Scopus BioPharma's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Scopus BioPharma (Scopus BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 300, New York, NY, USA, 10170
Scopus BioPharma Inc a biotechnology company focused on developing therapeutics targeting the endocannabinoid system. The endocannabinoid system is comprised of chemical compounds, or cannabinoids, that interact with cannabinoid receptors which are located throughout the body. The company product candidates would utilize synthetically-produced cannabinoids as opposed to plant-derived compounds. Its product candidate comprises CO-sTiRNA, which is a STAT3 inhibitor gene therapy and MRI-1867.
Executives
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
Joshua R Lamstein director, officer: Chairman 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Alan M Horsager officer: See Remarks 1021 N EVERETT STREET, GLENDALE CA 91207
Robert J Gibson director, officer: Vice Chairman 71 LANTERN RIDGE RD, NEW CANAAN CT 06840
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Iv David Weild director 22 ORIOLE AVENUE, BRONXVILLE NY 10708
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
David A. Buckel director SHARPSPRING, 550 SW 2ND AVENUE, GAINESVILLE FL 32601
Raphael Hofstein director C/O HADASSAH, P.O. BOX 12000, JERUSALEM L3 91120
Paul Hopper director 7982 DOUG HILL, SAN DIEGO CA 92127
Ashish P Sanghrajka director, officer: President 101 WALL STREET, APARTMENT 19B, NEW YORK NY 10005

Scopus BioPharma (Scopus BioPharma) Headlines

From GuruFocus

Scopus BioPharma to Present at the LD Micro Main Event

By Marketwired Marketwired 10-05-2021

Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders

By Marketwired Marketwired 09-28-2021